Febuxostat, a non-purine selective inhibitor of xanthine oxidase effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety.

被引：0

作者：

Khosravan, R ^{[1
]}

Mayer, M ^{[1
]}

Grabowski, B ^{[1
]}

Vernillet, L ^{[1
]}

Wu, JT ^{[1
]}

Joseph-Ridge, N ^{[1
]}

机构：

[1] TAP Pharmaceut Prod Inc, Lake Forest, IL USA

来源：

ARTHRITIS AND RHEUMATISM | 2004年 / 50卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：S337 / S337

页数：1

共 50 条

[1] Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase - Effect of renal impairment on pharmacokinetics, pharmacodynamics, and safety
Khosravan, R
Mayer, M
Wu, JT
Joseph-Ridge, N
Vernillet, L
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10): : 1195 - 1195
[2] Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase
Grabowski, Brian
Khosravan, Reza
Wu, Jing-Tao
Vernillet, Laurent
Lademacher, Christopher
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (01) : 57 - 64
[3] The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase
Khosravan, R
Grabowski, BA
Mayer, MD
Wu, JT
Joseph-Ridge, N
Vernillet, L
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (01): : 88 - 102
[4] Effect of renal impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat (TMX-67), a novel non-purine selective inhibitor of xanthine oxidase.
Swan, S
Khosravan, R
Mayer, MD
Wu, JT
Pa, WA
MacDonald, PA
Vernillet, L
Joseph-Ridge, N
[J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S529 - S529
[5] Pharmacokinetics, pharmacodynamics, and safety of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase, in healthy subjects
Grabowski, B
Khosravan, R
Vernillet, L
Wu, JT
Joseph-Ridge, N
Mulford, D
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10): : 1196 - 1196
[6] Pharmacokinetics, Pharmacodynamics and Safety of Febuxostat, a Non-Purine Selective Inhibitor of Xanthine Oxidase, in a Dose Escalation Study in Healthy Subjects
Reza Khosravan
Brian A. Grabowski
Jing-Tao Wu
Nancy Joseph-Ridge
Laurent Vernillet
[J]. Clinical Pharmacokinetics, 2006, 45 : 821 - 841
[7] Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects
Khosravan, Reza
Grabowski, Brian A.
Wu, Jing-Tao
Joseph-Ridge, Nancy
Vernillet, Laurent
[J]. CLINICAL PHARMACOKINETICS, 2006, 45 (08) : 821 - 841
[8] Effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat
Khosravan, R
Grabowski, B
Mayer, M
Wu, JT
Joseph-Ridge, N
Vernillet, L
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09): : 1083 - 1083
[9] Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia
Komoriya, K
Hoshide, S
Takeda, K
Kobayashi, H
Kubo, J
Tsuchimoto, M
Nakachi, T
Yamanaka, H
Kamatani, N
[J]. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2004, 23 (8-9): : 1119 - 1122
[10] Febuxostat: A Novel Non-Purine Selective Inhibitor of Xanthine Oxidase for the Treatment of Hyperuricemia in Gout
Yu, Kuang-Hui
[J]. RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2007, 1 (01) : 69 - 75

← 1 2 3 4 5 →